Healthcare Costs Following Medical Gender‐Affirmation: Evidence From Whole‐of‐Population Australian Administrative Data
Health Economics · 2026
DOI: 10.1002/hec.70127 ↗Kurz gefasst
Fachartikel in der Zeitschrift Health Economics, 2026. Verfasst von Karinna Saxby und 2 weiteren Autor:innen. Beteiligte Einrichtung: The Melbourne Institute of Applied Economic and Social Research, The University of Melbourne, Melbourne, Australia. Hauptthemen laut MEDLINE: Health Care Costs, Transgender Persons, Hormone Replacement Therapy, Health Expenditures. Die Arbeit nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Melbourne McKenzie Fellowship, National Health and Medical Research Council, Sylvia and Charles Viertel Charitable Foundation.
Abstract (Originalsprache)
Gender incongruence in trans and nonbinary (“trans”) populations is often associated with psychological distress and increased demand for mental healthcare. Gender‐affirming hormone therapy (GAHT) is a key component of care for many trans people, yet long‐term evidence around its cost implications remains limited despite increasing uptake and policy attention worldwide. We provide the first population‐based evidence on the healthcare costs of GAHT initiation using longitudinal administrative data from 32,313 trans Australians who initiated testosterone‐based GAHT (tGAHT) or estradiol‐based GAHT (eGAHT) between 2013 and 2024. Employing a dynamic difference‐in‐differences design, we estimate the impacts on government expenditure and patient out‐of‐pocket costs in the 6 years after initiation, using future initiators as controls. We find that initiating tGAHT leads to an additional AUD$3119 (USD$2246) in government expenditure and AUD$143 (USD$103) in out‐of‐pocket costs over 6 years; corresponding estimates were AUD$8348 (USD$6011) and AUD$1269 (USD$914) for eGAHT recipients. For tGAHT recipients, both government and out‐of‐pocket costs declined after initiation, with mental healthcare reductions exceeding ongoing hormone therapy expenditure after 6 years. For eGAHT recipients, costs also fell but remained above baseline, driven by sustained prescription spending. Taken together with quality‐of‐life benefits, our results suggest GAHT is likely to be cost‐effective.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Melbourne Institute of Applied Economic and Social Research, The University of Melbourne, Melbourne, Australia.
- Centre for Health Economics, Monash Business School, Caulfield, Australia.
- Trans Health Research Group, University of Melbourne, Melbourne, Victoria, Australia.
- Department of Endocrinology, Austin Health, Melbourne, Australia.
- Equinox Gender Diverse Clinic, Thorne Harbour Health, Abbotsford, Victoria, Australia.
ORCID-Profile: Karinna Saxby, Brendan J Nolan
Förderung
- University of Melbourne McKenzie Fellowship
- National Health and Medical Research Council
- Sylvia and Charles Viertel Charitable Foundation
Zitieren
APA
Saxby, K., Petrie, D., & Nolan, B. J. (2026). Healthcare Costs Following Medical Gender‐Affirmation: Evidence From Whole‐of‐Population Australian Administrative Data. Health Economics. https://doi.org/10.1002/hec.70127
Vancouver
Saxby K, Petrie D, Nolan BJ. Healthcare Costs Following Medical Gender‐Affirmation: Evidence From Whole‐of‐Population Australian Administrative Data. Health Economics. 2026. doi:10.1002/hec.70127
BibTeX
@article{Saxby2026,
author = {Saxby, Karinna and Petrie, Dennis and Nolan, Brendan J},
title = {Healthcare Costs Following Medical Gender‐Affirmation: Evidence From Whole‐of‐Population Australian Administrative Data},
journal = {Health Economics},
year = {2026},
doi = {10.1002/hec.70127}
}
EUVIMED